AAN 2023

AAN 2023: High-efficacy therapies slow disease progress faster in study

High-efficacy treatments for neuromyelitis optica spectrum disorder (NMOSD) are associated with significant reductions in hospitalizations, relapses, and MRI lesions relative to traditional therapies, according to a recent study. The findings, which were published in the Journal of Neurology, were discussed in an oral presentation at the American…

AAN 2023: NMOSD antibodies seen in blood years before symptoms

Antibodies against aquaporin-4 (AQP4) are detectable in the blood several years before symptoms occur in most people with neuromyelitis optica spectrum disorder (NMOSD), according to a U.S. study. Tammy Smith, MD, PhD, of the University of Utah, presented the findings at the recent American Academy of Neurology (AAN) annual…

AAN 2023: Enspryng still safe, effective after 4.5 years in trials

Up to 4.6 years of treatment with Enspryng (satralizumab) continues to safely reduce relapse rates and prevent disability progression for people with neuromyelitis optica spectrum disorder (NMOSD) who are positive for antibodies against aquaporin-4 (AQP4). That’s according to pooled data from the Phase 3 SAkuraSky (NCT02028884) and…